With some of its larger rivals already at work on biotech knockoffs, Indian drugmaker Lupin is on the hunt for partners to help shepherd it into the biosimilar fray, taking aim at top-selling treatments soon to come off patent.
As demand for biosimilar development swells around the world, CRO inVentiv Health has teamed up with Australia's Proteomics International to expand its characterization services, an effort to boost its capabilities in early work on biologic knockoffs.
Sanofi and its top-selling Lantus may have bought some time last month with a legal wrench in Eli Lilly's spokes, but now Merck has bulldozed its way into the conversation with plans to kick off late-stage studies for its own knockoff of the blockbuster drug, further complicating an already heated fight.
As more and more massive-selling biologics lose their patent protection, a new class of biosimilars is poised to blow up around the world, and the U.K.'s BioOutsource is amping up its capabilities to prepare for the boom.
As of last year, biotech products accounted for 71% of the revenue generated by the top 10 pharmaceutical-biotech products, according to a new report from the Tufts Center for the Study of Drug Development.
Daniel Galbraith By Daniel Galbraith 2013 was a landmark year for the development of biosimilars. With the global acceptance of biosimilars--also called "follow-on biologics" or...
Celltrion executives are manning the defenses this morning, insisting that the Korean biosimilars company did nothing wrong while confirming that they've fielded regulatory queries about possible insider trading. The allegations come at a particularly awkward time for Celltrion.
Today the European Commission made healthcare history with its first approval of a biosimilar antibody--Inflectra (infliximab)--which was developed by Korea's Celltrion and will be sold by generics powerhouse Hospira. But the companies don't expect to file for U.S. approval until 2015 as they wait for the FDA to finalize its regulatory pathway.
Amgen has won a key victory in its coast-to-coast campaign to persuade state legislatures to require a pharmacist to notify doctors any time they substitute a biosimilar for a branded biologic.
Now that the Swiss drugmaker has decided to forego a patent fight over the breast cancer drug in India, domestic drugmakers are rubbing their hands together in anticipation.